Targeted Drug Delivery Systems for Pancreatic Cancer

被引：35
作者：
Khare, Vaibhav [1 ]
Alam, Noor [1 ]
Saneja, Ankit [1 ]
Dubey, Ravindra Dhar [1 ]
Gupta, Prem N. [1 ]
机构：
[1] CSIR, Indian Inst Integrat Med, Formulat & Drug Delivery Div, Jammu 180001, India
来源：
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY | 2014年 / 10卷 / 12期
关键词：
Pancreatic Cancer; Targeted Drug Delivery; Nanomedicine; Novel Drug Delivery Systems; Ligand; Nanoparticles; ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; PEGYLATED-LIPOSOMAL DOXORUBICIN; INTERSTITIAL FLUID PRESSURE; PHASE-I; TRANSFERRIN RECEPTOR; POLYMERIC MICELLES; HYALURONIC-ACID; QUANTUM DOTS; DUCTAL ADENOCARCINOMA;
D O I：
10.1166/jbn.2014.2036
中图分类号：
TB3 [工程材料学];
学科分类号：
0805 ; 080502 ;
摘要：
Pancreatic cancer is usually diagnosed at the advanced stages, responds poorly to the available chemotherapeutics and constitutes the major factor for high mortality rate. Selective delivery of therapeutics to their cellular targets, without side effects is the foremost objective of the current investigations for effective treatment of pancreatic cancer. The development of the drugs which can selectively target pancreatic cancer along with carriers that can deliver drugs specifically to the rapidly dividing cells is considered as magic bullet for the efficient treatment of this fatal disease. This review describes various factors hampering the efficacy of drug targeting to pancreatic cancer including stromal fortress, hypocascularity, hyaluronan and interstitial fluid pressure, and exploration of various cellular targets for the site specific drug delivery. An account of burgeoning applications of novel drug delivery systems including nanoparticles, liposomes, quantum dots, micelles and drug conjugates in the management of pancreatic cancer is also provided. Additionally, potential of target based therapeutic agents and nanomedicines in clinical trials for the pancreatic cancer therapy are highlighted.
引用
收藏
页码：3462 / 3482
页数：21
相关论文
共 230 条
[11]  
Aubert M, 2000, INT J CANCER, V88, P558, DOI 10.1002/1097-0215(20001115)88:4<558::AID-IJC7>3.3.CO
[12]  
2-2
[13]   Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer [J].
Bailey, Jennifer M. ;
Swanson, Benjamin J. ;
Hamada, Tomofumi ;
Eggers, John P. ;
Singh, Pankaj K. ;
Caffery, Thomas ;
Ouellette, Michel M. ;
Hollingsworth, Michael A. .
CLINICAL CANCER RESEARCH, 2008, 14 (19) :5995-6004
[14]   Defining the Role of Integrin αvβ6 in Cancer [J].
Bandyopadhyay, A. ;
Raghavan, S. .
CURRENT DRUG TARGETS, 2009, 10 (07) :645-652
[15]   ABNORMALITIES OF THE P53 TUMOR SUPPRESSOR GENE IN HUMAN PANCREATIC-CANCER [J].
BARTON, CM ;
STADDON, SL ;
HUGHES, CM ;
HALL, PA ;
OSULLIVAN, C ;
KLOPPEL, G ;
THEIS, B ;
RUSSELL, RCG ;
NEOPTOLEMOS, J ;
WILLIAMSON, RCN ;
LANE, DP ;
LEMOINE, NR .
BRITISH JOURNAL OF CANCER, 1991, 64 (06) :1076-1082
[16]  
Bharali Dhruba J., 2009, Immunology Endocrine & Metabolic Agents in Medicinal Chemistry, V9, P219
[17]   Molecular targeted therapies for pancreatic cancer [J].
Borja-Cacho, Daniel ;
Jensen, Eric Hans ;
Saluja, Ashok Kumar ;
Buchsbaum, Donald J. ;
Vickers, Selwyn Maurice .
AMERICAN JOURNAL OF SURGERY, 2008, 196 (03) :430-441
[18]   Treatment of Pancreatic Cancer With an Oncolytic Adenovirus Expressing Interleukin-12 in Syrian Hamsters [J].
Bortolanza, Sergia ;
Bunuales, Maria ;
Otano, Itziar ;
Gonzalez-Aseguinolaza, Gloria ;
Ortiz-de-Solorzano, Carlos ;
Perez, Daniel ;
Prieto, Jesus ;
Hernandez-Alcoceba, Ruben .
MOLECULAR THERAPY, 2009, 17 (04) :614-622
[19]   Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin [J].
Boulikas, Teni .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (08) :1197-1218
[20]   Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [J].
Bouvet, M ;
Bold, RJ ;
Lee, J ;
Evans, DB ;
Abbruzzese, JL ;
Chiao, PJ ;
McConkey, DJ ;
Chandra, J ;
Chada, S ;
Fang, BL ;
Roth, JA .
ANNALS OF SURGICAL ONCOLOGY, 1998, 5 (08) :681-688
12345678910